Solutions for hemodialysis vascular access dysfunction: Thinking out of the box!!

Journal of Vascular Access

Volumn 6, Issue 1, 2005, Pages 3-8

  Roy Chaudhury, Prabir ^a   Melhem, M ^a   Husted, T ^a   Kelly, B S ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; POLITEF; POLYMER; RAPAMYCIN;

ANGIOPLASTY; ARTERIOVENOUS FISTULA; ARTERY INTIMA PROLIFERATION; BIOMEDICAL ENGINEERING; CANNULA; CLINICAL TRIAL; DRUG ELUTING STENT; EDITORIAL; ENDOTHELIUM CELL; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; NONHUMAN; RESTENOSIS; SMOOTH MUSCLE FIBER; STEM CELL; STENOSIS; TREATMENT FAILURE; VASCULAR ACCESS; VEIN ANASTOMOSIS;

EID: 20444500133     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980500600102     Document Type: Editorial

References (51)

1. Fitzgerald JT, Schanzer A, Chin AI, McVicar JP, Perez RV, Troppmann C. Outcomes of upper arm arteriovenous fistulas for maintenance hemodialysis access. Arch Surg 2004; 139 (2): 201-8.
2. Tordoir JH, Rooyens P, Dammers R, van der Sande FM, de Haan M, Yo TI. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for haemodialysis. Nephrol Dial Transplant 2003; 18 (2): 378-83.
3. Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis [clinical conference]. Kidney Int 1999; 55 (5): 2078-90.
4. Malovrh M. Native arteriovenous fistula: preoperative evaluation. Am J Kidney Dis 2002; 39 (6): 1218-25.
5. Patel ST, Hughes J, Mills JL, Sr. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality Initiative guidelines for hemodialysis access. J Vasc Surg 2003; 38 (3): 439-45; discussion 45.
6. Roy-Chaudhury P, Kelly BS, Zhang J, et al. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif 2003; 21 (1): 99-110.
7. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94 (7): 1655-64.
8. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8 (4): 403-9.
9. Rekhter M, Nicholls S, Ferguson M, Gordon D. Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb 1993; 13 (4): 609-17.
10. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80 (6): 1726-36.
11. Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59 (6): 2325-34.
12. Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR, Jr. Artery size, neointima, and remodeling: time for some standards. J Am Coll Cardiol 1998; 32 (7): 2087-94.
13. Ravani P, Brunori G, Mandolfo S, et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol 2004; 15 (1): 204-9.
14. Lee T, Barker J, Allon M. Associations with predialysis vascular access management. Am J Kidney Dis 2004; 43 (6): 1008-13.
15. Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 2003; 63 (1): 346-52.
16. Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K. Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 2003; 42 (5): 1000-12.
17. Faiyaz R, Abreo K, Zaman F, Pervez A, Zibari G, Work J. Salvage of poorly developed arteriovenous fistulae with percutaneous ligation of accessory veins. Am J Kidney Dis 2002; 39 (4): 824-7.
18. Dinwiddie LC. Interventions to promote fistula maturation. Nephrol Nurs J 2002; 29 (4): 377, 402.
19. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62 (4): 1109-24.
20. Sands J, Miranda CL. Increasing numbers of AV fistulas for hemodialysis access. Clin Nephrol 1997; 48 (2): 114-7.
21. Nugent HM, Groothuis A, Seifert P, et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 2002; 39 (6): 524-33.
22. Hoffer EK, Sultan S, Herskowitz MM, Daniels ID, Sclafani SJ. Prospective randomized trial of a metallic intravascular stent in hemodialysis graft maintenance. J Vasc Interv Radiol 1997; 8 (6): 965-73.
23. Beathard GA. The use of the Gianturco intravascular stent in stenotic hemodialysis fistulas. ASAIO Trans 1991; 37 (3): M234-5.
24. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23): 1773-80.
25. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350 (3): 221-31.
26. REALITY: Prospective, Randomized, Multicenter Head-to-Head Comparison of Cypher and Taxus Stent Systems. Medscape Internal Medicine, 2005. (Accessed April 16th, 2005, at http://www.medscape.com/viewarticle/501393.)
27. Rotmans JI, Pattynama PM, Verhagen HJ, et al. Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: a 4-week follow-up study. Circulation 2005; 111 (12): 1537-42.
28. Haskal. Stent Grafts. In: Society of Interventional Radiology; 2005; New Orleans; 2005.
29. Brauner R, Laks H, Drinkwater DC, Jr., et al. Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg 1997; 114 (1): 53-63.
30. Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ. Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Controlled Release 1999; 60 (1): 129-42.
31. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994; 93 (3): 1243-9.
32. Chaux A, Ruan XM, Fishbein MC, et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998; 115 (3): 604-12; discussion 12-4.
33. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA 1993; 90 (4): 1513-7.
34. Kaul S, Cercek B, Rengstrom J, et al. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. J Am Coll Cardiol 2000; 35 (2): 493-501.
35. Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100 (18): 1865-71.
36. Lopez JJ, Edelman ER, Stamler A, Morgan JP, Sellke FW, Simons M. Local perivascular administration of basic fibroblast growth factor: drug delivery and toxicological evaluation [published erratum appears in Drug Metab Dispos 1996; 24 (10): 1166]. Drug Metab Dispos 1996; 24 (8): 922-4.
37. Golomb G, Fishbein I, Banai S, et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996; 125 (2): 171-82.
38. Kelly B, Melhem M, Desai P, Kasting G, Zhang J, Li J, Heffelfinger S, Rudich S, Roy-Chaudhury P. Perivascular Paclitaxel Polymers Reduce Neointimal Hyperplasia and Venous Stenosis in PTFE Arteriovenous Grafts: A Solution for Hemodialysis Vascular Access Dysfunction? J Am Soc Nephrol (ASN 2004 abstract).
39. Masaki T, Rathi R, Zentner G, et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 2004; 66 (5): 2061-9.
40. Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93 (8): 783-90.
41. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111 (7): 926-31.
42. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95 (4): 343-53.
43. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93 (2): e17-24.
44. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108 (21): 2710-5.
45. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003; 107 (24): 3093-100.
46. Kong D, Melo LG, Gnecchi M, et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004; 110 (14): 2039-46.
47. Bhattacharya V, McSweeney PA, Shi Q et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood 2000; 95 (2): 581-5.
48. He H, Shirota T, Yasui H, Matsuda T. Canine endothelial progenitor cell-lined hybrid vascular graft with nonthrombogenic potential. J Thorac Cardiovasc Surg 2003; 126 (2): 455-64.
49. Shirota T, Yasui H, Shimokawa H, Matsuda T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials 2003; 24 (13): 2295-302.
50. Ong AT, Aoki J, Kutryk MJ, Serruys PW. How to accelerate the endothelialization of stents. Arch Mal Coeur Vaiss 2005; 98 (2): 123-6.
51. Frost MC, Reynolds MM, Meyerhoff ME. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials 2005; 26 (14): 1685-93.